Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia

DOI: PM/8140075
Presse Medicale, 1994, 23, 73-7.

#	Paper	IF	Citations
52	Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count. *Annals of Hematology*, **1994**, 69, 81-4	3	62
51	The determination of spontaneous megakaryocyte colony formation is an unequivocal test for discrimination between essential thrombocythaemia and reactive thrombocytosis. *British Journal of Haematology*, **1995**, 90, 326-31	4.5	32
50	The myeloproliferative disorders. An historical appraisal and personal experiences. *Leukemia and Lymphoma*, **1996**, 22 Suppl 1, 1-14	1.9	17
49	Acquired von Willebrand disease in myeloproliferative disorders. *Leukemia and Lymphoma*, **1996**, 22 Suppl 1, 79-82	1.9	29
48	Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. *Leukemia and Lymphoma*, **1996**, 22 Suppl 1, 149-60	1.9	46
47	Bleeding time and platelet function in essential thrombocythemia and other myeloproliferative syndromes. *Leukemia and Lymphoma*, **1996**, 22 Suppl 1, 71-8	1.9	45
46	Interferon-alpha in the treatment of essential thrombocythemia. *Leukemia and Lymphoma*, **1996**, 22 Suppl 1, 135-42	1.9	66
45	Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia. *Leukemia and Lymphoma*, **1996**, 22 Suppl 1, 47-56	1.9	59
44	The Management of Polycythaemia Vera. *Hematology*, **1997**, 2, 55-64	2.2	1
43	Portal vein thrombosis in a 17-year-old female adolescent with essential thrombocytosis. *Pediatric Hematology and Oncology*, **1997**, 14, 457-62	1.7	6
42	The use of aspirin in polycythaemia vera and primary thrombocythaemia. *Blood Reviews*, **1998**, 12, 12-22	11.1	21
41	Correlation of Thrombosis With Increased Platelet Turnover in Thrombocytosis. *Blood*, **1998**, 91, 1288-1294	9.4	83
40	Acquired von Willebrand disease due to increasing platelet count can readily explain the paradox of thrombosis and bleeding in thrombocythemia. *Clinical and Applied Thrombosis/Hemostasis*, **1999**, 5, 147-51	3.3	31
39	Thrombosis and bleeding in myeloproliferative disorders: identification of at-risk patients with whole blood platelet aggregation studies. *British Journal of Haematology*, **1999**, 105, 618-25	4.5	33
38	Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. *Best Practice and Research in Clinical Haematology*, **2001**, 14, 401-36	4.2	111
37	Current treatment practice for essential thrombocythaemia in adults. *Expert Opinion on Pharmacotherapy*, **2001**, 2, 385-93	4	2
36	Acquired von Willebrand syndrome: its pathophysiology, laboratory features and management. *Journal of Thrombosis and Thrombolysis*, **2003**, 15, 141-9	5.1	23

35	Acute myelogenous leukemia associated with extreme symptomatic thrombocytosis and chromosome 3q translocation: case report and review of literature. *American Journal of Hematology*, **2003**, 72, 20-6	7.1	15
34	Thrombocythaemia and pregnancy. *Best Practice and Research in Clinical Haematology*, **2003**, 16, 227-42	4.2	48
33	Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera. *Platelets*, **2004**, 15, 67-84	3.6	73
32	Risk-adapted therapy in essential thrombocythemia and polycythemia vera. *Blood Reviews*, **2005**, 19, 243-52	11.1	65
31	Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. *British Journal of Haematology*, **2005**, 128, 275-90	4.5	371
30	Essential thrombocythemia. *Seminars in Hematology*, **2005**, 42, 230-8	4	39
29	Evidence-based management of polycythemia vera. *Best Practice and Research in Clinical Haematology*, **2006**, 19, 483-93	4.2	12
28	Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention. *Best Practice and Research in Clinical Haematology*, **2006**, 19, 617-33	4.2	68
27	Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. *Platelets*, **2006**, 17, 528-44	3.6	80
26	Acquired von Willebrand syndrome: features and management. *American Journal of Hematology*, **2006**, 81, 616-23	7.1	69
25	Thrombocytosis: Essential Thrombocythemia and Reactive Causes. **2007**, 295-318		
24	Options in the management of essential thrombocythaemia. *European Journal of Haematology*, **2007**, 79, 35-9	3.8	3
23	Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. *Leukemia*, **2008**, 22, 1494-502	10.7	84
22	Role of platelet counts in the management of essential thrombocythemia: experience with anagrelide. *Expert Review of Hematology*, **2009**, 2, 227-36	2.8	4
21	Thrombohemorrhagic complications of myeloproliferative disorders. *Blood Reviews*, **2010**, 24, 227-32	11.1	39
20	How I treat the acquired von Willebrand syndrome. *Blood*, **2011**, 117, 6777-85	2.2	239
19	Aspirin in low-risk essential thrombocythemia, not so simple after all?. *Leukemia Research*, **2011**, 35, 286-9	2.7	13
18	How to manage essential thrombocythemia. *Leukemia*, **2012**, 26, 875-82	10.7	23

17	Management of myeloproliferative neoplasms: from academic guidelines to clinical practice. *Current Hematologic Malignancy Reports*, **2012**, 7, 50-6	4.4	19
16	Thrombocytosis. **2013**, 298-323		2
15	Assessing disease burden in patients with classic MPNs. *Best Practice and Research in Clinical Haematology*, **2014**, 27, 107-19	4.2	6
14	Essential thrombocythemia-related stroke and improvement with tissue plasminogen activator. *American Journal of the Medical Sciences*, **2015**, 350, 152	2.2	2
13	Ischemic stroke with essential thrombocythemia: a case series. *Journal of Stroke and Cerebrovascular Diseases*, **2015**, 24, 890-3	2.8	20
12	Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort. *International Journal of Hematology*, **2015**, 102, 587-93	2.3	22
11	Thrombotic risk correlates with mutational status in true essential thrombocythemia. *European Journal of Clinical Investigation*, **2016**, 46, 683-9	4.6	10
10	Acute compartment syndrome as the initial manifestation of chronic-phase chronic myeloid leukemia: a case report and review of the literature. *Journal of Medical Case Reports*, **2016**, 10, 201	1.2	4
9	Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden. *Annals of Hematology*, **2017**, 96, 1297-1302	3	22
8	Thrombocytosis: Essential Thrombocythemia and Reactive Causes. **2019**, 346-373		
7	Development of Alveolar Hemorrhage in a Patient with Acute Myocardial Infarction Complicated with Essential Thrombocythemia. *American Journal of Case Reports*, **2021**, 22, e928409	1.3	1
6	Cutaneous pathology in primary erythermalgia. *American Journal of Dermatopathology*, **1996**, 18, 30-4	0.9	30
5	Myeloproliferative and thrombotic burden and treatment outcome of thrombocythemia and polycythemia patients. *World Journal of Critical Care Medicine*, **2015**, 4, 230-9	3	7
4	Risk Classification. **2012**, 71-84		
3	Interferon Therapy of Essential Thrombocythemia and Polycythemia Vera. **1997**, 67-83		
2	PAI-1 und t-PA bei Patienten mit Thrombozytosen im Rahmen von chronischen myeloproliferativen Erkrankungen. **1997**, 337-347		
1	Practical management of the haemorrhagic complications of myeloproliferative neoplasms. *British Journal of Haematology*,	4.5	1